Navigation Links
Romark Announces Clinical Trial Results for New Influenza Drug Presented at IDSA Meeting 2011
Date:10/21/2011

se group and 116.7 hours for patients receiving the placebo. Time to resolution of symptoms for the low dose group were less than for the placebo, but the difference was not statistically significant (P=0.521). Patients in the 600 mg NTZ treatment group also experienced statistically significant reductions in quantitative viral shedding compared to patients receiving the placebo (P=0.0006). Adverse events were similar for the three treatment groups except for a higher rate of mild diarrhea in the 600 mg treatment group (8.1%) compared to the placebo treatment group (3.3%).

About the Phase 2 Clinical Trials

Two Phase 2 clinical trials, one in pediatric patients age 1 to 11 years, and another in adults and adolescents age 12 – 65 years, were conducted at a single center in Cajamarca, Peru.  Patients were enrolled based upon symptoms consistent with influenza (fever, at least one respiratory symptom and one constitutional symptom) and randomly assigned to receive treatment with NTZ or placebo in double-blind fashion.  Patients in the pediatric study received 100 mg NTZ (age 12 – 47 months), 200 mg NTZ (age 4 – 11 years) or placebo twice daily for five days as an oral suspension.  Patients enrolled in the study of adults and adolescents received 500 mg NTZ or placebo twice daily for five days as an oral tablet.  Identification of respiratory viruses at baseline was performed by ELISA.  Patients were visited daily by a study nurse to monitor the health of the patients, ensure compliance with the study medication and recording of symptoms in a patient diary, and to collect tissue with nasal secretions, and patients were followed up at study day 7.  The primary efficacy endpoint was time from first dose to alleviation of symptoms (all symptoms absent or mild and remained so for 24 hours).  

One-hundred children, median age 3 years, were enrolled in the pediatric trial (50 per tre
'/>"/>

SOURCE Romark Laboratories, L.C.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
2. Romark Laboratories Raises $18 Million in Institutional Financing
3. Romark Laboratories Initiates Phase II Study of Nitazoxanide in Treatment-Naive Patients With Chronic Hepatitis C Genotype 1
4. Romark Announces Presentation of New Data for Nitazoxanide in Chronic Hepatitis C at EASL 2008
5. Romark Laboratories Completes Enrollment in U.S. Phase II Study of Nitazoxanide for Chronic Hepatitis C Genotype 1 Non-Responders
6. Romark Initiates Clinical Trial of Alinia for Treatment of Influenza
7. NeuroFocus and New Scientist Magazine Apply Neuromarketing to Select Cover Design
8. Intercell and Romark Join Forces in Combining Therapies Against Hepatitis C
9. Romark and Intercell Join Forces in Combining Therapies Against Hepatitis C
10. Romark Announces Data Presented at AASLD Meeting 2010
11. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... NORWALK, Conn. , Aug. 27, 2014  UBM ... , a leading online community for medical imaging professionals, ... Association for Medical Imaging Management,s 2014 Annual Meeting ... the conference coverage: , 11 Principles ... management can lead to greater profitability. , ...
(Date:8/27/2014)... , Aug. 27, 2014 /PRNewswire-iReach/ -- Emergency ... design, blended emergency medical training and response technologies, ... defibrillator) training from the Department of Homeland ... Reserve 81 st Regional Support Command ... contract includes nationwide CPR/AED/First Aid training. The Army ...
(Date:8/27/2014)... , Aug. 27, 2014   Auxilium Pharmaceuticals , Inc. ... biopharmaceutical company, today announced that certain members of the ... Healthcare Conference to be held September 8-10, 2014 in ... , Chief Executive Officer and President, is scheduled to ... portfolio at 10:55 a.m. ET on Wednesday, September 10, ...
Breaking Medicine Technology:Diagnostic Imaging Covers Association for Medical Imaging Management (AHRA) 2014 Meeting 2Diagnostic Imaging Covers Association for Medical Imaging Management (AHRA) 2014 Meeting 3Emergency University Equips Homeland Security, Army Reserve with SCA Response Program to Save Lives of Sudden Cardiac Arrest Victims 2Emergency University Equips Homeland Security, Army Reserve with SCA Response Program to Save Lives of Sudden Cardiac Arrest Victims 3Auxilium Pharmaceuticals, Inc. To Present At The Morgan Stanley Healthcare Conference 2Auxilium Pharmaceuticals, Inc. To Present At The Morgan Stanley Healthcare Conference 3
... Quark Pharmaceuticals, Inc., a pharmaceutical company engaged in ... it has dosed the first patient with recent onset ... ongoing Phase I study of QPI-1007, the Company,s proprietary ... The Phase I open-label, dose-escalation study was initiated ...
... PHILADELPHIA, Oct. 20 ERT (Nasdaq: ... for the third quarter 2010 on Thursday, November 4, 2010, ... host a conference call at 5:00 PM EDT that day. ... dial 1-800-860-2442 when calling within the United States or 1-412-858-4600 ...
Cached Medicine Technology:Quark Pharmaceuticals Doses First Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION) Patient in Stratum II of its Clinical Study of siRNA Drug Candidate QPI-1007 2Quark Pharmaceuticals Doses First Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION) Patient in Stratum II of its Clinical Study of siRNA Drug Candidate QPI-1007 3ERT to Announce Third Quarter 2010 Results on November 4, 2010 2
(Date:8/27/2014)... For nearly two decades, audiences around the world ... Deva Premal & Miten with their rapturous Nepali flute ... album in May, their 2014 MANTRAS FOR LIFE TOUR ... globe, including Russia, Ukraine, Israel, Australia, the U.S., Canada, ... new album and a new five-piece band, the love ...
(Date:8/27/2014)... positive hospital blood culture samples are discarded every day ... skin germs instead of specific disease-causing bacteria. , ... clinicians may be able to use the resistance profiles ... patients with antibiotics appropriate to their ailment, Tel Aviv ... Alon of TAU,s Sackler Faculty of Medicine and the ...
(Date:8/27/2014)... (PRWEB) August 27, 2014 According ... Market Research "Ablation Technologies Market (Applications: Cardiovascular, Gynecology, ... Electrical, Ultrasound, Microwave, Cryotherapy) - Global Industry Analysis, ... 2020," the global ablation technologies market was valued ... estimated to reach a market worth USD 10,611 ...
(Date:8/27/2014)... NH 8/27/14)Dartmouth cancer researchers developed and tested an ... environmental interactions that contribute to disease as published ... , The approach fills a gap in current ... complex interactions among genetic and environmental factors. When ... interactions versus those that reflect chance combinations among ...
(Date:8/27/2014)... 2014 Nava Beauty Store and Spa aims ... patrons from those seeking luxury care products to the everyday ... high end luxurious brands like Valmont and Elemis to cater ... brands like Dermalogica and Bliss to provide easy to use ... also offer purely organic skin care products such as Jurlique, ...
Breaking Medicine News(10 mins):Health News:Deva Premal & Miten's Mantras For Life Tour Announced 2Health News:Deva Premal & Miten's Mantras For Life Tour Announced 3Health News:'Junk' blood tests may offer life-saving information 2Health News:Global Ablation Technologies Market Expected to Reach USD 10.6 Billion in 2020: Transparency Market Research 2Health News:Global Ablation Technologies Market Expected to Reach USD 10.6 Billion in 2020: Transparency Market Research 3Health News:Global Ablation Technologies Market Expected to Reach USD 10.6 Billion in 2020: Transparency Market Research 4Health News:Global Ablation Technologies Market Expected to Reach USD 10.6 Billion in 2020: Transparency Market Research 5Health News:Dartmouth isolates environmental influences in genome-wide association studies 2Health News:Nava Beauty Store Announce Grand Opening in Great Neck, New York 2
... in the United States who undergo surgery to have ... a recent study shows that men who have their ... cancer returns . ,Researchers studied more than 500 ... study first had a radical prostatectomy and also underwent ...
... is the most common bacterial illness in children and ... of children may be getting treated unnecessarily with antibiotics ... they don’t need them may build up antibiotic resistance, ... a more serious infection. ,According to the new ...
... that certain hormones in the body may yield a ... events and death in people with no symptoms. Researchers ... the current standards used to diagnose heart failure. ... the participants’ blood looking for specific substances and compared ...
... their risk of birth defects. Now, new research shows ... say about 31,000 stroke-related deaths and about 17,000 heart ... fortification was implemented. ,Folic acid lowers homocysteine levels. ... risk for stroke and heart disease. Specialists from the ...
... new study shows the use of antibacterial products, such ... reduce the risk of infectious// disease symptoms in the ... households in New York with at least one preschool-age ... household cleaning and personal hygiene products that contained antibacterial ...
... study suggests drinking extra fluids may do more harm ... ,Researchers examined results from previous studies to determine if ... safe. Previous data has shown during a respiratory infection, ... large amounts of a specific hormone that conserves water. ...
Cached Medicine News:
... High Throughput Screening (UHTS), Analyst GT ... Allows for smooth transfer of assays ... sharing all the detection modalities of ... fluorescence polarization, time-resolved fluorescence, luminescence, absorbance, ...
... Ultra High Throughput Screening (UHTS), Analyst ... performance. Allows for smooth transfer of ... by sharing all the detection modalities ... intensity, fluorescence polarization, time-resolved fluorescence, luminescence, ...
... exclusively for cell-based assays, the NOVOstar provides ... to the flexibility of an on-board reagent ... plate to plate or from three reagent ... the unit has two injectors that can ...
... cDNA and Oligonucleotides The Tecan GENios ... variety applications that are quantified by Fluorescence, Absorbance ... assays in Microplate formats from 6 to ... Cuvettes Independent whether you have to quantitate ...
Medicine Products: